Vanda Pharmaceuticals (VNDA) Amortization - Intangibles (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly Amortization - Intangibles of $2.0 million in Q1 2026, up 16.4% quarter-over-quarter from $1.7 million in Q4 2025, and up 13.41% year-over-year from $1.8 million in Q1 2025.
Vanda Pharmaceuticals' Amortization - Intangibles history runs 17 years deep, the most recent figure standing at $2.0 million for Q1 2026.
- In Q1 2026, Amortization - Intangibles rose 13.41% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $7.3 million (up 2.67% YoY), while the FY2025 annual figure was $7.0 million, down 3.66% from the prior year.
- Amortization - Intangibles came in at $2.0 million for Q1 2026 at Vanda Pharmaceuticals, up from $1.7 million in the prior quarter.
- In the past five years, Amortization - Intangibles ranged from a high of $2.0 million in Q1 2024 to a low of $379000.0 in Q3 2022.
- A 5-year average of $1.2 million and a median of $1.7 million in 2025 frame the typical range for Amortization - Intangibles.
- Across the five-year window, Amortization - Intangibles soared 432.45% in 2024 and fell 13.18% in 2025, its largest moves.
- Vanda Pharmaceuticals' Amortization - Intangibles stood at $416000.0 in 2022, then jumped by 129.09% to $953000.0 in 2023, then jumped by 83.84% to $1.8 million in 2024, then dropped by 2.57% to $1.7 million in 2025, then grew by 16.4% to $2.0 million in 2026.
- According to Business Quant data, Amortization - Intangibles over the past three periods registered $2.0 million, $1.7 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.99 Mn |
| Dec 31, 2025 | 1.71 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.75 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 953,000.00 |
| Sep 30, 2023 | 400,000.00 |
| Jun 30, 2023 | 400,000.00 |
| Mar 31, 2023 | 379,000.00 |
| Dec 31, 2022 | 416,000.00 |
| Sep 30, 2022 | 379,000.00 |
| Jun 30, 2022 | 400,000.00 |
| Mar 31, 2022 | 400,000.00 |
| Dec 31, 2021 | 369,000.00 |
| Sep 30, 2021 | 370,000.00 |
| Jun 30, 2021 | 369,000.00 |
| Mar 31, 2021 | 400,000.00 |
| Dec 31, 2020 | 378,000.00 |
| Sep 30, 2020 | 369,000.00 |
| Jun 30, 2020 | 369,000.00 |
| Mar 31, 2020 | 400,000.00 |
| Dec 31, 2019 | 405,000.00 |
| Sep 30, 2019 | 376,000.00 |
| Jun 30, 2019 | 379,000.00 |
| Mar 31, 2019 | 400,000.00 |
| Dec 31, 2018 | 427,000.00 |
| Sep 30, 2018 | 400,000.00 |
| Jun 30, 2018 | 400,000.00 |
| Mar 31, 2018 | 352,000.00 |
| Dec 31, 2017 | 450,000.00 |
| Sep 30, 2017 | 432,000.00 |
| Jun 30, 2017 | 432,000.00 |
| Mar 31, 2017 | 454,000.00 |
| Dec 31, 2016 | 2.11 Mn |
| Sep 30, 2016 | 2.94 Mn |
| Jun 30, 2016 | 2.94 Mn |
| Mar 31, 2016 | 2.94 Mn |
| Dec 31, 2015 | 2.94 Mn |
| Sep 30, 2015 | 2.94 Mn |
| Jun 30, 2015 | 2.94 Mn |
| Mar 31, 2015 | 4.14 Mn |
| Dec 31, 2014 | 536,000.00 |
| Sep 30, 2014 | 536,000.00 |
| Jun 30, 2014 | 617,000.00 |
| Mar 31, 2014 | 565,000.00 |
| Dec 31, 2013 | 377,000.00 |
| Sep 30, 2013 | 377,000.00 |
| Jun 30, 2013 | 372,000.00 |
| Mar 31, 2013 | 369,000.00 |
| Dec 31, 2012 | 377,000.00 |
| Sep 30, 2012 | 377,000.00 |
| Jun 30, 2012 | 372,000.00 |
| Mar 31, 2012 | 369,000.00 |
| Dec 31, 2011 | 377,000.00 |
| Sep 30, 2011 | 377,000.00 |
| Jun 30, 2011 | 372,000.00 |
| Mar 31, 2011 | 369,000.00 |
| Dec 31, 2010 | 377,000.00 |
| Sep 30, 2010 | 377,000.00 |
| Jun 30, 2010 | 372,000.00 |